Albireo Pharma (ALBO) Reports Q1 Loss of $0.15, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 falls from record high as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Albireo Provides First Quarter 2018 Business Update
May 17, 2018 7:30 AM EDTÂ First patient enrolled in Phase 3 trial of IBAT inhibitor A4250 in PFICÂ
 Elobixibat in Japan becomes first IBAT inhibitor approved in the worldÂ
 Management to host conference call and webcast today at 8:30 a.m. EDTÂ
BOSTON, May 17, 2018 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today provided corporate highlights for the beginning of 2018.
The beginning of 2018 has been a landmark period for Albireo, said Ron Cooper, President and... More
